IGC Pharma Broadens Medication Range to Include Metabolic Diseases with IGC-1A, a Possible New GLP-1 Agonist.

Azitra Reveals Initial Patient Screening and Enrollment Plans for Phase 1b ATR-12 Trial in Netherton Syndrome.

Innovo Therapeutics Inc. Unveils Phase 2 Clinical Data Highlighting the Breakthrough Effectiveness of INV-001 for Post-Thyroidectomy Scar Treatment.

The U.S. has approved RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) as an initial treatment without chemotherapy for patients with advanced lung cancer and EGFR mutations.

Sonnet BioTherapeutics Signs Clinical Collaboration for Investigator-Led, Funded Phase 1/2a Trial of SON-1210 with Chemotherapy in Pancreatic Cancer.

Aug 22nd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

China's NMPA Grants Approval for PADCEV™ (Enfortumab Vedotin) to Treat Advanced or Metastatic Urothelial Cancer.

TEPKINLY® (epcoritamab) Gains Another European Commission Nod for Adult Relapsed/Refractory Follicular Lymphoma Treatment.

The U.S. FDA has removed the partial clinical hold previously imposed on MediLink Therapeutics' (Suzhou) Co., Ltd. Phase I trial, which is assessing BNT326/YL202 (NCT05653752) and was disclosed on June 17, 2024.

Apogee Therapeutics Starts Phase 1 Trial for APG990, a New Long-Lasting OX40L Antibody for Atopic Dermatitis and Inflammatory Diseases, with Initial Participants Dosed.

ImmuneSensor Therapeutics Gains Approval from Australian Authorities to Begin First-in-Human Phase 1 Trial for cGAS Inhibitor Drug IMSB301.

GlycoNex has declared the successful conclusion of a Phase 1 clinical trial for its denosumab biosimilar, SPD8.